Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-240
- Development stage
- Phase 1
- Lead developer
- Laboratorios Sophia
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**PRO-240** is an investigational fixed-dose ophthalmic lubricating solution developed by Laboratorios Sophia for dry eye disease and ocular-surface discomfort. The formulation contains propylene glycol 0.3%, polyethylene glycol 400 0.5%, and glycerin 0.2%; these demulcent and lubricant components are intended to protect and lubricate the ocular surface and support tear-film stability. It is being evaluated in a Phase 1 safety and tolerability study in ophthalmologically and clinically healthy adult volunteers versus Optive. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06375343))
- Brand names
- Trehalosa Sophia
- Other names
- PRO 240PRO240PRO-240
Beyond the preview
Go deeper on PRO-240.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-240.